Llwytho...
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development
As the first clinical proteasome inhibitor, Bortezomib (BTZ) has been reported to improve the outcome of lymphoma. However, due to the unstable property, low bioavailability, and hydrophobic properties of BTZ, it is needed to develop effective drug delivery systems to deliver BTZ into targeted cells...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Aging (Albany NY) |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Impact Journals
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7835069/ https://ncbi.nlm.nih.gov/pubmed/33290262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.202146 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|